– USA, NM – NTx, a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced the appointment of Dave Johnson to its Board of Directors.
About Dave Johnson
Dave Johnson is a seasoned leader in M&A and corporate strategy, with more than 120 acquisitions representing over $40 billion in equity investment, divestitures, and venture capital transactions. He co-founded TLG Capital Partners and previously served as Senior Managing Director at The Blackstone Group, where he led technology sector investments across cybersecurity, cloud solutions, and IT services.
Earlier in his career, Dave Johnson was SVP of Strategy at Dell, where he drove major acquisitions including SecureWorks and Boomi, and held senior leadership roles at IBM. He has also served on numerous corporate boards.
Dave Johnson holds a B.A. and an MBA from Boston College, as well as a PMD from Harvard University.
About NTx
NTx, based in Rio Rancho, New Mexico, is revolutionizing biomanufacturing with cutting-edge solutions tailored to the demands of modern research and personalized medicine. NTx is developing innovative systems like NTxscribe and NTxpress to enable the sustainable production of mRNA and protein therapeutics, offering scalability from personalized doses to mass-market volumes.
For more: https://ntxbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.